Sledge Jr. GW, et al. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. LBA6_PR. ESMO 2019. 28 sep.-1 okt. 2019, Barcelona, Spanje.
Distributed learning: leren van elkaars data met waarborging van patiënt-privacy
nov 2019 | Radiotherapie